PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE

The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or...

Full description

Saved in:
Bibliographic Details
Main Authors MUNTENDAM, PIETER, MICHAELS, SCOTT A, LARSEN, GLENN R
Format Patent
LanguageEnglish
French
Published 15.06.2021
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery. La présente invention concerne des formulations pharmaceutiques liquides de furosémide. Lesdites formulations pharmaceutiques incluent un excès molaire de tris(hydroxyméthyl)aminométhane par rapport au furosémide, et présentent un pH situé dans la plage de 7 à 8,5 et une concentration de tris(hydroxyméthyl)aminométhane supérieure ou égale à environ 50 mM. La présente invention permet d'améliorer la stabilité de formulations pharmaceutiques liquides incluant du furosémide et l'aptitude à l'usage de ces formulations pharmaceutiques pour leur administration ou leur apport sous-cutané.
Bibliography:Application Number: CA20142908935